These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8422722)

  • 1. Study of the tumor marker carbohydrate antigen 50 in liver cirrhosis. Pathogenetic considerations.
    Collazos J; Genolla J; Ruibal A
    Clin Nucl Med; 1993 Jan; 18(1):56-9. PubMed ID: 8422722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and laboratory evaluation of CA 19-9 in cirrhotic patients.
    Collazos J
    Eur J Med; 1992; 1(4):215-8. PubMed ID: 1341447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of CA 50 in nonmalignant liver diseases: a clinical and biochemical study.
    Collazos J; Genolla J; Ruibal A
    Am J Gastroenterol; 1993 Mar; 88(3):409-12. PubMed ID: 8438849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical and laboratory evaluation of the behavior of tissue polypeptide antigen in liver cirrhosis.
    Collazos J; Genollá J; Ruibal A
    Digestion; 1992; 53(3-4):157-61. PubMed ID: 1291404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer-associated antigen CA 15.3 in liver cirrhosis.
    Collazos J; Genolla J; Ruibal A
    Acta Oncol; 1992; 31(7):741-4. PubMed ID: 1476754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosis.
    Fabris C; Basso DA; Leandro G; Meggiato T; Elba S; Panozzo MP; Del Favero G; Fogar P; Di Mario F; Naccarato R
    Cancer; 1991 Oct; 68(8):1795-8. PubMed ID: 1717126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA 19-9 in non-neoplastic liver diseases. A clinical and laboratory study.
    Collazos J; Genolla J; Ruibal A
    Clin Chim Acta; 1992 Sep; 210(1-2):145-51. PubMed ID: 1424156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA 15.3 in nonmalignant liver diseases.
    Collazos J; Genollá J; Ruibal A
    Int J Biol Markers; 1991; 6(3):188-92. PubMed ID: 1791313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis.
    Schöniger-Hekele M; Müller C
    Dig Dis Sci; 2006 Feb; 51(2):338-45. PubMed ID: 16534678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The reliability of highly elevated CA 19-9 levels.
    Osswald BR; Klee FE; Wysocki S
    Dis Markers; 1993 Dec; 11(5-6):275-8. PubMed ID: 8082316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis.
    Giannini E; Borro P; Botta F; Chiarbonello B; Fasoli A; Malfatti F; Romagnoli P; Testa E; Risso D; Lantieri PB; Antonucci A; Boccato M; Milone S; Testa R
    Int J Biol Markers; 2000; 15(3):226-30. PubMed ID: 11012098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the behavior of carcinoembryonic antigen in cirrhotic patients.
    Collazos J; Genollà J; Ruibal A
    Int J Biol Markers; 1992; 7(4):244-8. PubMed ID: 1491181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA 125 serum levels in patients with non-neoplastic liver diseases. A clinical and laboratory study.
    Collazos J; Genolla J; Ruibal A
    Scand J Clin Lab Invest; 1992 May; 52(3):201-6. PubMed ID: 1411252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.
    Kuusela P; Haglund C; Roberts PJ
    Br J Cancer; 1991 Apr; 63(4):636-40. PubMed ID: 2021550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of serum CA 195 and carcinoembryonic antigen in metastatic carcinoma.
    Verdi CJ; Ahmann FR; Schifman RB; Elvick AL; Ahmann ME; Marx PC
    Cancer; 1993 Jun; 71(11):3625-32. PubMed ID: 8490911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Carbohydrate antigens CA 19-9, CA 242, CA 50 in liver diseases].
    Nowak J; Jakubowska D; Wiczkowski A; Sprzaczkowska K; Stechły T; Zmudziński W; Grzesik P; Walas R; Jarzab B
    Wiad Lek; 1998; 51(11-12):484-91. PubMed ID: 10222840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass.
    Schutter EM; Davelaar EM; van Kamp GJ; Verstraeten RA; Kenemans P; Verheijen RH
    Am J Obstet Gynecol; 2002 Aug; 187(2):385-92. PubMed ID: 12193930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of a relationship between high serum CA 125 and liver failure pattern in cirrhotic patients without ascitis and jaundice.
    Ruibal A; Siuriana R
    Int J Biol Markers; 1986; 1(1):55-6. PubMed ID: 2447203
    [No Abstract]   [Full Text] [Related]  

  • 20. [Diagnostic usefulness of Ca 19-9 antigen in cancer of the pancreas and neoplasms of the pancreato-biliary intersection].
    Robles-Diáz G; Aceves G; Galván E
    Gac Med Mex; 1990; 126(2):78-82; discussion 82-3. PubMed ID: 2387490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.